Business Description
Scinai Immunotherapeutics Ltd
ISIN : US09073Q1058
Share Class Description:
FRA:2F5: ADRDescription
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.84 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | 0.16 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -10.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -110.7 | |||||
| 3-Year FCF Growth Rate | 51.2 | |||||
| 3-Year Book Growth Rate | 37 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 87.31 | |||||
| 9-Day RSI | 75.41 | |||||
| 14-Day RSI | 67.34 | |||||
| 6-1 Month Momentum % | 6.38 | |||||
| 12-1 Month Momentum % | -44.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.16 | |||||
| Quick Ratio | 1.16 | |||||
| Cash Ratio | 0.74 | |||||
| Days Sales Outstanding | 96.5 | |||||
| Days Payable | 542.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -59.1 | |||||
| Shareholder Yield % | 202.11 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 7.74 | |||||
| Operating Margin % | -1813.72 | |||||
| Net Margin % | 806.2 | |||||
| FCF Margin % | -1485.54 | |||||
| ROE % | Neg. Equity | |||||
| ROA % | 22.71 | |||||
| ROIC % | -68.98 | |||||
| ROC (Joel Greenblatt) % | 57.02 | |||||
| ROCE % | 45.62 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 0.84 | |||||
| PS Ratio | 5.85 | |||||
| PB Ratio | 0.73 | |||||
| Price-to-Tangible-Book | 0.73 | |||||
| EV-to-EBIT | 1.37 | |||||
| EV-to-EBITDA | 1.15 | |||||
| EV-to-Revenue | 19.88 | |||||
| EV-to-FCF | -1.34 | |||||
| Earnings Yield (Greenblatt) % | 72.88 | |||||
| FCF Yield % | -209.27 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Scinai Immunotherapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.415 | ||
| EPS (TTM) (€) | -7.164 | ||
| Beta | -1.09 | ||
| Volatility % | 68.48 | ||
| 14-Day RSI | 67.34 | ||
| 14-Day ATR (€) | 0.084974 | ||
| 20-Day SMA (€) | 3.192 | ||
| 12-1 Month Momentum % | -44.95 | ||
| 52-Week Range (€) | 2.5 - 7.3 | ||
| Shares Outstanding (Mil) | 0.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Scinai Immunotherapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Scinai Immunotherapeutics Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Scinai Immunotherapeutics Ltd Frequently Asked Questions
What is Scinai Immunotherapeutics Ltd(FRA:2F5)'s stock price today?
The current price of FRA:2F5 is €3.52. The 52 week high of FRA:2F5 is €7.30 and 52 week low is €2.50.
When is next earnings date of Scinai Immunotherapeutics Ltd(FRA:2F5)?
The next earnings date of Scinai Immunotherapeutics Ltd(FRA:2F5) is 2025-02-22 Est..
Does Scinai Immunotherapeutics Ltd(FRA:2F5) pay dividends? If so, how much?
Scinai Immunotherapeutics Ltd(FRA:2F5) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers